CA2405413A1 - Inhibition of cytokine generation - Google Patents

Inhibition of cytokine generation Download PDF

Info

Publication number
CA2405413A1
CA2405413A1 CA002405413A CA2405413A CA2405413A1 CA 2405413 A1 CA2405413 A1 CA 2405413A1 CA 002405413 A CA002405413 A CA 002405413A CA 2405413 A CA2405413 A CA 2405413A CA 2405413 A1 CA2405413 A1 CA 2405413A1
Authority
CA
Canada
Prior art keywords
desloratadine
allergic
basophils
inhibition
generation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002405413A
Other languages
English (en)
French (fr)
Inventor
Robert P. Schleimer
John Schroeder
William Kreutner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2405413A1 publication Critical patent/CA2405413A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002405413A 2000-04-07 2001-04-05 Inhibition of cytokine generation Abandoned CA2405413A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19601600P 2000-04-07 2000-04-07
US60/196,016 2000-04-07
PCT/US2001/011474 WO2001076600A2 (en) 2000-04-07 2001-04-05 Inhibition of cytokine generation

Publications (1)

Publication Number Publication Date
CA2405413A1 true CA2405413A1 (en) 2001-10-18

Family

ID=22723784

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002405413A Abandoned CA2405413A1 (en) 2000-04-07 2001-04-05 Inhibition of cytokine generation

Country Status (6)

Country Link
EP (1) EP1267870A2 (es)
JP (1) JP2003530351A (es)
AU (1) AU2001255268A1 (es)
CA (1) CA2405413A1 (es)
MX (1) MXPA02009821A (es)
WO (1) WO2001076600A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Also Published As

Publication number Publication date
MXPA02009821A (es) 2003-03-27
EP1267870A2 (en) 2003-01-02
AU2001255268A1 (en) 2001-10-23
WO2001076600A3 (en) 2002-06-27
JP2003530351A (ja) 2003-10-14
WO2001076600A2 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
Du Buske Clinical comparison of histamine H1–receptor antagonist drugs
EP3337486B1 (en) Deuterated compounds and uses thereof
Grant et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial
Simons H1-antihistamines in children
Hurst et al. Ebastine: an update of its use in allergic disorders
US20030229030A1 (en) Method of treating interleukin-6-mediated inflammatory diseases
Murdoch et al. Desloratadine: an update of its efficacy in the management of allergic disorders
Keam et al. Rupatadine: a review of its use in the management of allergic disorders
Handley et al. Therapeutic advantages of third generation antihistamines
Terrien et al. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen
US20060276495A1 (en) Treatment methods of nasal congestion and nasal obstruction
US20080262018A1 (en) Treating allergic and inflammatory conditions
US6599914B2 (en) Inhibition of cytokine generation
CA3174416A1 (en) Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions
Kontou-Fili et al. Suppression of histamine-induced skin reactions by loratadine and cetirizine diHCl
Wasserfallen et al. Effect of cetirizine, a new H1 antihistamine, on the early and late allergic reactions in a bronchial provocation test with allergen
CN107635564B (zh) 人参皂苷m1用于预防或治疗硅肺病的用途
TW202333726A (zh) 以ｓｓａｏ抑制劑治療肝病
Day Pros and cons of the use of antihistamines in managing allergic rhinitis
CA2405413A1 (en) Inhibition of cytokine generation
US20080221104A1 (en) Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis
Yu et al. Donepezil blocks voltage-gated ion channels in rat dissociated hippocampal neurons
Vivero et al. A close look at fenfluramine and dexfenfluramine
Mittal et al. Second-generation antihistamines
Ibrahim et al. Study of the correlation between clozapine levels and clinical findings in acutely intoxicated patients admitted to poison control Center-Ain Shams University hospitals: 6 months (a prospective study)

Legal Events

Date Code Title Description
FZDE Dead